SMTI
Sanara MedTech Inc.
Next earnings Aug 11, 2026 · consensus $-0.03 EPS, $29.5M rev
Last earnings -2.1% on 2026-05-11
$23.88
▲ +3.29%$23.88▼ -14.16%
over 1Y
L $16.34EODHDH $35.75
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.3%
1W+9.8%
1M+2.1%
3M+40.8%
YTD+3.4%
1Y-14.2%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Revenue grew 19.0% YoY; but unprofitable (net margin -36.4%).
Revenue (FY2025) $103M · FY2025
Sanara MedTech Inc. shows $103M in FY2025 revenue (+19.0% YoY), a -36.4% net margin, and -632.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $24.1M | $45.8M | $65.0M | $86.7M | $103M |
| Gross profit | $21.8M | $39.5M | $57.1M | $78.5M | $95.6M |
| Operating income | -$7.38M | -$12.5M | -$4.22M | $1.26M | $7.30M |
| Net income | -$7.92M | -$7.94M | -$4.30M | -$9.66M | -$37.6M |
| Diluted EPS | — | -$1.00 | -$0.52 | -$1.14 | -$4.36 |
| Net margin | -32.8% | -17.3% | -6.6% | -11.2% | -36.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$249M
EV / EBITDA22.1
EV / Sales2.4
EV / FCF115.2
P / FCF101.3
PEG (trailing)—
Earnings yield-17.2%
FCF yield1.0%
Quality & risk
ROIC (est.)11.0%
Free cash flow$2.16M
Total debt$46.6M
Net cash-$30.0M
Altman Z-Score2.50 grey
Piotroski F-Score4/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+3.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-06-04). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-042026-06-09open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗8-KPeriod ending 2026-06-022026-06-04open ↗4Period ending 2026-05-152026-05-18open ↗10-QPeriod ending 2026-03-312026-05-12open ↗
Frequently asked
- Is Sanara MedTech Inc. (SMTI) a buy?
- SMTI currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 19.0% YoY; but unprofitable (net margin -36.4%).
- What is Sanara MedTech Inc.'s quality score?
- SMTI scores 48.49019607843137/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000714256, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 8:36:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.